CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) - USD ($) shares in Millions, $ in Millions	Total	Shareholders' Equity [Member]	Common Stock [Member]	Add'l Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accum. Other Comp. Loss [Member]		Noncontrolling Interests [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)			9,407
Beginning balance at Dec. 31, 2020	$ 63,473	$ 63,238	$ 470	$ 88,674	$ (110,988)	$ 90,392	$ (5,310)		$ 235
Beginning balance (in shares) at Dec. 31, 2020					(3,840)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	10,475	10,440				10,440			35
Other comprehensive income/(loss), net of tax	556	552					552		3
Cash dividends declared, per share
Common stock	(4,377)	(4,377)				(4,377)
Share-based payment transactions (in shares)			43		11
Share-based payment transactions	221	221	$ 2	662	$ (368)	(76)
Purchases of common stock	0
Other	(33)	(33)				(33)
Ending balance (in shares) at Jul. 04, 2021			9,450
Ending balance at Jul. 04, 2021	70,315	70,042	$ 472	89,336	$ (111,356)	96,346	(4,758)		273
Ending balance (in shares) at Jul. 04, 2021					(3,851)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)			9,445
Beginning balance at Apr. 04, 2021	68,865	68,620	$ 472	89,002	$ (111,349)	95,158	(4,664)		245
Beginning balance (in shares) at Apr. 04, 2021					(3,851)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	5,589	5,563				5,563			26
Other comprehensive income/(loss), net of tax	(92)	(94)					(94)		2
Cash dividends declared, per share
Common stock	(4,293)	(4,293)				(4,293)
Share-based payment transactions (in shares)			5
Share-based payment transactions	251	251		334	$ (7)	(76)
Purchases of common stock	0
Other	(6)	(6)				(7)
Ending balance (in shares) at Jul. 04, 2021			9,450
Ending balance at Jul. 04, 2021	70,315	70,042	$ 472	89,336	$ (111,356)	96,346	(4,758)		273
Ending balance (in shares) at Jul. 04, 2021					(3,851)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)			9,450
Beginning balance (in shares)			9,471
Beginning balance at Dec. 31, 2021	77,462	77,201	$ 473	90,591	$ (111,361)	103,394	(5,897)		262
Beginning balance (in shares) at Dec. 31, 2021					(3,851)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	17,781	17,769				17,769			12
Other comprehensive income/(loss), net of tax	(1,228)	(1,223)					(1,223)	[1]	(6)
Cash dividends declared, per share
Common stock	(4,489)	(4,489)				(4,489)
Share-based payment transactions (in shares)			25		12
Share-based payment transactions	(53)	(53)	$ 2	588	$ (578)	(66)
Purchases of common stock (in shares)					(39)
Purchases of common stock	(2,000)	(2,000)			$ (2,000)
Other	(4)	3		3					(7)
Ending balance (in shares) at Jul. 03, 2022			9,496
Ending balance at Jul. 03, 2022	87,469	87,208	$ 476	91,183	$ (113,939)	116,608	(7,119)		261
Ending balance (in shares) at Jul. 03, 2022					(3,903)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)			9,494
Beginning balance at Apr. 03, 2022	82,685	82,424	$ 476	90,844	$ (113,931)	111,193	(6,157)		261
Beginning balance (in shares) at Apr. 03, 2022					(3,903)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	9,911	9,906				9,906			6
Other comprehensive income/(loss), net of tax	(968)	(963)					(963)		(5)
Cash dividends declared, per share
Common stock	(4,489)	(4,489)				(4,489)
Share-based payment transactions (in shares)			2
Share-based payment transactions	330	330		339	$ (8)	(2)
Purchases of common stock	0
Other	0
Ending balance (in shares) at Jul. 03, 2022			9,496
Ending balance at Jul. 03, 2022	$ 87,469	$ 87,208	$ 476	$ 91,183	$ (113,939)	$ 116,608	$ (7,119)		$ 261
Ending balance (in shares) at Jul. 03, 2022					(3,903)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)			9,496

[1] Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses related to our equity method investment in the Consumer Healthcare JV (see Note 2C) and the impact of our net investment hedging program.